NorthWest Biotherapeutics Inc (NWBO)

[abc1212]

Was good until your maths went a bit wrong.

There are 200,000 GBM patients worldwide each year. After UK approval MD's worldwide will start directing their patients to DCVAXL. With a patient's life depending on it Im sure at least 5% to 10% can afford DCVAXL treatment of let's say $150k. So let's assume 1000 patients of these 200,000 patients worldwide will, after UK approval, get DCVAXL treatment in 2025 x $150k = $150 million revenue x 10 multiplier makes a deserved 1.5 billion market cap for NWBO, which should take us above $1. However, the problem remains OTC.

As you said, 200,000 worldwide and if you took your lowest figure of 5%, that would be 10,000 not 1000

Going by your figures with a 10x multiple, that would give us an SP of over $10